Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Biotech Industry Analysis

UpdatedAug 12, 2026
DataAggregated Company Financials
Companies540
  • 7D4.9%
  • 3M12.4%
  • 1Y41.3%
  • YTD16.7%

In the last week, the Biotech industry is up 4.9%, with Amgen leading the way with a 6.2% gain. Meanwhile, Sionna Therapeutics actually underperformed within the industry, shrinking 90% in the last week. This takes the industry's 12 month performance to a gain of 41%. Earnings are forecast to grow by 27% annually.

Industry Valuation and Performance

Has the U.S. Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 12 Aug 2026US$1.5tUS$172.5b-US$20,868,466,792.5916.4x-69.9x8.5x
Fri, 10 Jul 2026US$1.5tUS$169.9b-US$12,258,246,103.4717.8x-119x8.6x
Sun, 07 Jun 2026US$1.3tUS$170.0b-US$12,160,280,783.8216.6x-104.3x7.5x
Tue, 05 May 2026US$1.3tUS$167.5b-US$11,616,741,742.2517.2x-108.9x7.6x
Thu, 02 Apr 2026US$1.3tUS$166.1b-US$11,596,621,749.1814.9x-110.9x7.7x
Sat, 28 Feb 2026US$1.3tUS$169.4b-US$13,319,467,287.6121.7x-101.1x7.9x
Mon, 26 Jan 2026US$1.3tUS$163.5b-US$15,173,296,321.8319.9x-83.6x7.8x
Wed, 24 Dec 2025US$1.2tUS$163.6b-US$15,779,683,760.8721.6x-78.8x7.6x
Fri, 21 Nov 2025US$1.2tUS$163.8b-US$16,219,175,263.2117.4x-73.7x7.3x
Sun, 19 Oct 2025US$1.2tUS$163.4b-US$18,206,489,780.5816.4x-64.1x7.1x
Tue, 16 Sep 2025US$1.1tUS$163.6b-US$18,378,517,336.6815.8x-58.3x6.6x
Thu, 14 Aug 2025US$1.0tUS$163.2b-US$14,658,010,083.9415.6x-70.7x6.4x
Sat, 12 Jul 2025US$985.4bUS$155.8b-US$23,408,172,286.8618.5x-42.1x6.3x
Mon, 09 Jun 2025US$951.3bUS$155.9b-US$23,930,730,032.6116.8x-39.8x6.1x
Wed, 07 May 2025US$949.3bUS$154.1b-US$25,408,936,426.3418.3x-37.4x6.2x
Fri, 04 Apr 2025US$791.2bUS$118.6b-US$37,117,653,368.2221.5x-21.3x6.7x
Sun, 02 Mar 2025US$850.7bUS$118.9b-US$37,265,127,499.9717x-22.8x7.2x
Tue, 28 Jan 2025US$983.3bUS$149.5b-US$26,320,225,889.8517.1x-37.4x6.6x
Thu, 26 Dec 2024US$990.4bUS$149.9b-US$26,369,148,329.0016x-37.6x6.6x
Sat, 23 Nov 2024US$1.0tUS$150.0b-US$26,559,949,256.4417x-37.7x6.7x
Mon, 21 Oct 2024US$908.0bUS$113.1b-US$35,950,283,773.0221.7x-25.3x8x
Wed, 18 Sep 2024US$929.9bUS$113.2b-US$35,966,527,614.9422.9x-25.9x8.2x
Fri, 16 Aug 2024US$870.9bUS$113.2b-US$36,254,285,538.6422.2x-24x7.7x
Sun, 14 Jul 2024US$1.2tUS$164.5b-US$28,119,714,352.8429.4x-42.5x7.3x
Tue, 11 Jun 2024US$1.2tUS$164.5b-US$26,797,092,425.0728.1x-43.3x7.1x
Thu, 09 May 2024US$1.1tUS$164.6b-US$26,520,766,232.3824.3x-42.5x6.8x
Sat, 06 Apr 2024US$1.1tUS$164.4b-US$23,433,178,577.0325x-47.8x6.8x
Mon, 04 Mar 2024US$1.2tUS$167.9b-US$21,330,880,627.7515.9x-56.4x7.2x
Wed, 31 Jan 2024US$1.4tUS$204.7b-US$22,654,596,727.0017.8x-63.8x7.1x
Fri, 29 Dec 2023US$1.4tUS$204.9b-US$22,192,805,164.0019.9x-62.8x6.8x
Sun, 26 Nov 2023US$1.2tUS$204.8b-US$22,013,452,568.0018.6x-55.7x6x
Tue, 24 Oct 2023US$1.2tUS$207.5b-US$13,040,981,709.0016.2x-93x5.8x
Thu, 21 Sep 2023US$1.3tUS$207.5b-US$12,879,934,249.0016.5x-99.1x6.1x
Sat, 19 Aug 2023US$1.3tUS$207.6b-US$12,299,327,844.0017.4x-102.8x6.1x
Price to Earnings Ratio

-102.8x


Total Market Cap: US$1.3tTotal Earnings: -US$12,299,327,844.00Total Revenue: US$207.6bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Biotech Industry Price to Earnings3Y Average -60.1x202420252026
Current Industry PE
  • Investors are optimistic on the American Biotechs industry, and appear confident in long term growth rates.
  • The 3-year average PS ratio of 7.0x is lower than the industry's current PS ratio of 8.5x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have deteriorated over the last three years.
  • Revenues have also declined 6.0% per year.
  • This means overall sales from these companies are declining and losses are subsequently expanding as well.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market0.091%
Healthcare3.58%
Biotech4.92%
Biotech4.92%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
AMGN AmgenUS$414.306.2%
+US$13.1b		45.4%PE25.6x
VRTX Vertex PharmaceuticalsUS$529.6510.6%
+US$12.9b		36.6%PE30.5x
ABBV AbbVieUS$250.092.6%
+US$11.1b		25.9%PE70.5x
INSM InsmedUS$132.5734.2%
+US$7.5b		8.7%PS25.4x
NTRA NateraUS$312.7213.6%
+US$5.7b		95.7%PS16.7x

Latest News

TNGX
US$26.34
Tango Therapeutics
7D
-10.3%
1Y
289.6%
EXEL
US$51.33
Exelixis
7D
-8.3%
1Y
35.3%
RVMD
US$205.55
Revolution Medicines
7D
6.2%
1Y
483.0%
SION
US$5.10
Sionna Therapeutics
7D
-89.8%
1Y
-75.7%
TENX
US$1.62
Tenax Therapeutics
7D
-88.3%
1Y
-72.5%
ONC
US$359.27
BeOne Medicines
7D
11.2%
1Y
24.7%
COGT
US$38.70
Cogent Biosciences
7D
-9.7%
1Y
235.1%
TYRA
US$25.18
Tyra Biosciences
7D
-22.6%
1Y
137.5%
NTRA
US$312.72
Natera
7D
13.6%
1Y
95.7%
BIIB
US$203.89
Biogen
7D
-2.2%
1Y
58.1%
NBIX
US$161.94
Neurocrine Biosciences
7D
-2.5%
1Y
25.6%
REGN
US$797.00
Regeneron Pharmaceuticals
7D
4.8%
1Y
43.2%
INSM
US$132.57
Insmed
7D
34.2%
1Y
8.7%
Narrative Update • Aug 08

INSM: Respiratory Franchise Execution Will Outweigh Index Removal And Launch Concerns

Insmed's updated analyst price target has moved from $141.28 to $161.00. This reflects analysts' focus on the Brinsupri launch trajectory, revised revenue and margin assumptions, and a higher future P/E multiple anchored in recent research that clusters price targets mostly in the $169 to $218 range.
AMGN
US$414.30
Amgen
7D
6.2%
1Y
45.4%
ABBV
US$250.09
AbbVie
7D
2.6%
1Y
25.9%
Narrative Update • Aug 07

ABBV: Future Returns Will Hinge On Apogee Respiratory Bet

Analysts have nudged their fair value estimate for AbbVie higher to about $273 per share. This reflects refreshed models that factor in Q2 updates, stronger confidence in long term margins, and the potential impact of the Apogee acquisition, while still using a slightly higher discount rate and a modestly lower future P/E assumption.
VRTX
US$529.65
Vertex Pharmaceuticals
7D
10.6%
1Y
36.6%
Narrative Update • Aug 04

VRTX: Endocrinology Expansion And Nephrology Pipeline Will Drive Next Phase

Analysts have nudged their price targets on Vertex Pharmaceuticals higher, generally into a $550 to $605 range, citing raised FY26 revenue guidance, steady cystic fibrosis performance, and a growing set of potential catalysts across hematology, nephrology, pain, and the newly added endocrinology portfolio. Analyst Commentary Street research on Vertex Pharmaceuticals points to a generally constructive tone, with multiple firms lifting price targets and focusing on execution around the cystic fibrosis franchise, the expanding pipeline and the new endocrinology pillar from the Crinetics deal.